MAGNIFY Phase 3b Study of Lenalidomide plus Rituximab (R2) Followed by Maintenance in Relapsed/ Refractory Indolent Non-Hodgkin Lymphoma: Complete Induction Phase Analysis

Frederick Lansigan,David Jacob Andorsky,Morton Coleman,Abdulraheem Yacoub,Jason M. Melear,Suzanne R. Fanning,Kathryn S. Kolibaba,Chris Reynolds,Grzegorz S. Nowakowski,Mecide Gharibo,Jung Ryun Ahn,Ju Li,Mathias J. Rummel,Jeff P. Sharman

Blood（2022）

引用 4|浏览26

暂无评分

摘要

These data represent a complete analysis of all patients in the induction phase of MAGNIFY that continue to support that R2 is active with a tolerable safety profile in patients with R/R FL grade 1-3a and MZL, including rituximab-refractory, double-refractory, and early relapse patients.

查看译文

关键词

IBCL,follicular lymphoma,IMiD,marginal zone,rituximab,Phase III

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要